The global generic injectables market for the period between 2019 and 2026. An in-depth and unbiased market assessment has been made, which offers an in-depth and accurate analysis. Market projections have been offered in terms of value (US$ Mn). Stakeholders of this report include companies and intermediaries engaged in manufacturing and distribution of generic injectable products as well as new entrants planning to enter this market.
The global generic injectables market has been studied for the forecast period of 2019 to 2026. For research, 2018 has been considered as the base year and 2017 as the historical year, while all forecasts have been provided from 2019 to 2026. The global generic injectables market report comprises an elaborate executive summary that provides overall information about various segments of the market. The report provides a detailed competitive landscape, by major players operating in this market along with their shares (value %) of the global generic injectables market for 2018. The report also provides detail company profiles of emerging market players operating in the global generic injectables market.
The market overview section comprises factors such as key market dynamics including drivers, restraints, and opportunities affecting the demand for generic injectable products in the global market. These factors are likely to aid stakeholders establish a strong foothold in the global generic injectables market. Furthermore, the market overview section comprises key industry events, product overview, and market attractiveness analysis in the global generic injectables market. The market attractiveness analysis provides a graphical view comparing the expansion and market dynamics in various segments and countries to identify the most attractive market.
Generic Injectables Market - Scope
The global generic injectables market has been segmented based on product type, container type applications, and route of administration. In terms of product type, the global generic injectables market has been bifurcated into large molecule injectables, also known as generic biologics or biosimilar products, and small molecule injectables. The large molecule injectables segment has been further sub-segmented into monoclonal antibodies {monoclonal antibodies (mAbs)}, insulin, and others. Based on container type, the global generic injectables market has been categorized into vials, ampoules, premixes, prefilled syringes, and others. In terms of application, the global generic injectables market has been categorized into oncology, infectious diseases, cardiology, diabetes, immunology, and others. Based on route of administration, the global generic injectables market has been categorized into intravenous, intramuscular, subcutaneous, and others.
In terms of geography, the global generic injectables market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, analysis for major countries comprising the U.S., Canada, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Australia & New Zealand, Brazil, Mexico, South Africa, Israel, and GCC Countries has also been provided in the report. A detailed qualitative analysis of the factors responsible for driving and restraining the generic injectables market in various regions has been provided in this section.
The report renders a detailed outline/blueprint of the generic injectables market globally that is expected to assist new companies establish their presence and market players expand their share in the market. The report concludes with the company profile section, which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies, and recent developments.
Competitive landscape
Major players operating in the global generic injectables market include Pfizer Inc., Novartis AG (Sandoz International GmbH), Baxter, Fresenius SE & Co. KGaA, Mylan N.V., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC., Lupin Ltd., and Sanofi, Biocon. Other prominent players operating in the global generic injectables market include Dr. Reddy’s Laboratories, Aurobindo Pharma, Sagent Pharmaceuticals Inc., Zydus Cadila, GlaxoSmithKline plc, and AstraZeneca plc.
The global generic injectables market has been segmented into:
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentations
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.1.1. Product Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Generic Injectables Market Analysis and Forecasts, 2017–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
4.6. Market Outlook
4.7. Global Generic Products Market Condition Overview: by Key Countries
4.8. Biosimilars: Pipeline Analysis
4.9. Generic Injectables Market: Mergers & Acquisitions
4.10. Global Generics: Industry Trends
4.11. EU and USFDA Approved Biosimilar Products Snapshot
4.12: Regulatory Framework for Biosimilar Products
4.13: Top 10 Players in the U.S. Generic Injectables Market: Company Share Analysis and Market Competition Overview Per Product
4.14. Challenges Faced by Biosimilar Products to be Approved in the U.S. Market
5. Global Generic Injectables Market Analysis and Forecasts, by Product Type,
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Market Value Forecast by Product Type, 2017–2026
5.3.1. Large Molecule Injectables (Biosimilars)
5.3.1.1. Monoclonal Antibodies (mAbs)
5.3.1.2. Insulin
5.3.1.3. Others
5.3.2. Small Molecule Injectables
5.4. Market Attractiveness by Product Type
6. Global Generic Injectables Market Analysis and Forecasts, by Container Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast by Container Type, 2017–2026
6.3.1. Vials
6.3.2. Premixes
6.3.3. Prefilled Syringes
6.3.4. Ampoules
6.3.5. Other
6.4. Market Attractiveness by Container Type
7. Global Generic Injectables Market Analysis and Forecasts, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast by Application, 2017–2026
7.3.1. Oncology
7.3.2. Infectious Diseases
7.3.3. Cardiology
7.3.4. Diabetes
7.3.5. Immunology
7.3.6. Others
7.4. Market Attractiveness by Route of Administration
8. Global Generic Injectables Market Analysis and Forecasts, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast by Route of Administration, 2017–2026
8.3.1. Intravenous
8.3.2. Intramuscular
8.3.3. Subcutaneous
8.3.4. Others
8.4. Market Attractiveness, by Route of Administration
9. Global Generic Injectables Market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Market Value Forecast by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Country/ Sub-region
10. North America Global Generic Injectables Market Analysis and Forecast
10.1.Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product Type, 2017–2026
10.2.1. Large Molecule Injectables (Biosimilars)
10.2.1.1. Monoclonal Antibodies (mAbs)
10.2.1.2. Insulin
10.2.1.3. Others
10.2.2. Small Molecule Injectables
10.3. Market Value Forecast, by Container Type, 2017–2026
10.3.1. Vials
10.3.2. Premixes
10.3.3. Prefilled Syringes
10.3.4. Ampoules
10.3.5. Others
10.4. Market Value Forecast, by Application, 2017–2026
10.4.1. Oncology
10.4.2. Infectious Diseases
10.4.3. Cardiology
10.4.4. Diabetes
10.4.5. Immunology
10.4.6. Others
10.5. Market Value Forecast, by Route of Administration, 2017–2026
10.5.1. Intravenous
10.5.2. Intramuscular
10.5.3. Subcutaneous
10.5.4. Others
10.6. Market Value Forecast, by Country, 2017–2026
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Product Type
10.7.2. By Container Type
10.7.3. By Route of Administration
10.7.4. By Route of Administration
10.7.5. By Country
11. Europe Global Generic Injectables Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2017–2026
11.2.1. Large Molecule Injectables (Biosimilars)
11.2.1.1. Monoclonal Antibodies (mAbs)
11.2.1.2. Insulin
11.2.1.3. Others
11.2.2. Small Molecule Injectables
11.3. Market Value Forecast, by Container Type, 2017–2026
11.3.1. Vials
11.3.2. Premixes
11.3.3. Prefilled Syringes
11.3.4. Ampoules
11.3.5. Other
11.4. Market Value Forecast, by Application, 2017–2026
11.4.1. Oncology
11.4.2. Infectious Diseases
11.4.3. Cardiology
11.4.4. Diabetes
11.4.5. Immunology
11.4.6. Others
11.5. Market Value Forecast, by Route of Administration, 2017–2026
11.5.1. Intravenous
11.5.2. Intramuscular
11.5.3. Subcutaneous
11.5.4. Others
11.6. Market Value Forecast, by Country, 2017–2026
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Spain
11.6.5. Italy
11.6.6. Russia
11.6.7. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Product Type
11.7.2. By Container Type
11.7.3. By Application
11.7.4. By Route of Administration
11.7.5. By Country
12. Asia Pacific Global Generic Injectables Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017–2026
12.2.1. Large Molecule Injectables (Biosimilars)
12.2.1.1. Monoclonal Antibodies (mAbs)
12.2.1.2. Insulin
12.2.1.3. Others
12.2.2. Small Molecule Injectables
12.3. Market Value Forecast, by Container Type, 2017–2026
12.3.1. Vials
12.3.2. Premixes
12.3.3. Prefilled Syringes
12.3.4. Ampoules
12.3.5. Other
12.4. Market Value Forecast, by Application, 2017–2026
12.4.1. Oncology
12.4.2. Infectious Diseases
12.4.3. Cardiology
12.4.4. Diabetes
12.4.5. Immunology
12.4.6. Others
12.5. Market Value Forecast, by Route of Administration, 2017–2026
12.5.1. Intravenous
12.5.2. Intramuscular
12.5.3. Subcutaneous
12.5.4. Others
12.6. Market Value Forecast, by Country, 2017–2026
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Product Type
12.7.2. By Container Type
12.7.3. By Route of Administration
12.7.4. By Route of Administration
12.7.5. By Country
13. Latin America Global Generic Injectables Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017–2026
13.2.1. Large Molecule Injectables (Biosimilars)
13.2.1.1. Monoclonal Antibodies (mAbs)
13.2.1.2. Insulin
13.2.1.3. Others
13.2.2. Small Molecule Injectables
13.3. Market Value Forecast, by Container Type, 2017–2026
13.3.1. Vials
13.3.2. Premixes
13.3.3. Prefilled Syringes
13.3.4. Ampoules
13.3.5. Others
13.4. Market Value Forecast, by Application, 2017–2026
13.4.1. Oncology
13.4.2. Infectious Diseases
13.4.3. Cardiology
13.4.4. Diabetes
13.4.5. Immunology
13.4.6. Others
13.5. Market Value Forecast, by Route of Administration, 2017–2026
13.5.1. Intravenous
13.5.2. Intramuscular
13.5.3. Subcutaneous
13.5.4. Others
13.6. Market Value Forecast, by Country, 2017–2026
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Product Type
13.7.2. By Container Type
13.7.3. By Route of Administration
13.7.4. By Route of Administration
13.7.5. By Country
14. Middle East & Africa Global Generic Injectables Market Analysis and Forecast
14.1.Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Type, 2017–2026
14.2.1. Large Molecule Injectables (Biosimilars)
14.2.1.1. Monoclonal Antibodies (mAbs)
14.2.1.2. Insulin
14.2.1.3. Others
14.2.2. Small Molecule Injectables
14.3. Market Value Forecast, by Container Type, 2017–2026
14.3.1. Vials
14.3.2. Premixes
14.3.3. Prefilled Syringes
14.3.4. Ampoules
14.3.5. Other
14.4. Market Value Forecast, by Application, 2017–2026
14.4.1. Oncology
14.4.2. Infectious Diseases
14.4.3. Cardiology
14.4.4. Diabetes
14.4.5. Immunology
14.4.6. Others
14.5. Market Value Forecast, by Route of Administration, 2017–2026
14.5.1. Intravenous
14.5.2. Intramuscular
14.5.3. Subcutaneous
14.5.4. Others
14.6. Market Value Forecast, by Country, 2017–2026
14.6.1. GCC Countries
14.6.2. Israel
14.6.3. South Africa
14.6.4. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Product Type
14.7.2. By Container Type
14.7.3. By Route of Administration
14.7.4. By Route of Administration
14.7.5. By Country
15. Competition Landscape
15.1. Market Player – Competition Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis by Company (2016)
15.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.3.1. Pfizer Inc.
15.3.1.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.1.2 Financial Overview
15.3.1.3 Product Portfolio
15.3.1.4 SWOT Analysis
15.3.1.5 Strategic Overview
15.3.2. Novartis AG (Sandoz International GmbH)
15.3.2.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.2.2 Financial Overview
15.3.2.3 Product Portfolio
15.3.2.4 SWOT Analysis
15.3.3. Baxter
15.3.3.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.3.2 Financial Overview
15.3.3.3 Product Portfolio
15.3.3.4 SWOT Analysis
15.3.3.5 Strategic Overview
15.3.4. Fresenius SE & Co. KGaA
15.3.4.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.4.2 Financial Overview
15.3.4.3 Product Portfolio
15.3.4.4 SWOT Analysis
15.3.4.5 Strategic Overview
15.3.5. Mylan N.V.
15.3.5.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.5.2 Financial Overview
15.3.5.3 Product Portfolio
15.3.5.4 SWOT Analysis
15.3.5.5 Strategic Overview
15.3.6. Teva Pharmaceutical Industries Ltd.
15.3.6.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.6.2 Financial Overview
15.3.6.3 Product Portfolio
15.3.6.4 SWOT Analysis
15.3.6.5 Strategic Overview
15.3.7. Hikma Pharmaceuticals PLC.
15.3.7.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.7.2 Financial Overview
15.3.7.3 Product Portfolio
15.3.7.4 SWOT Analysis
15.3.7.5 Strategic Overview
15.3.8. Lupin Ltd.
15.3.8.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.8.2 Financial Overview
15.3.8.3 Product Portfolio
15.3.8.4 SWOT Analysis
15.3.8.5 Strategic Overview
15.3.9. Sanofi
15.3.9.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.9.2 Financial Overview
15.3.9.3 Product Portfolio
15.3.9.4 SWOT Analysis
15.3.9.5 Strategic Overview
15.3.10. Biocon
15.3.10.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.10.2 Financial Overview
15.3.10.3 Product Portfolio
15.3.10.4 SWOT Analysis
15.3.10.5 Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers